"We see molnupiravir, with its oral format as a clear game changer that is likely to meaningfully impact not just the treatment paradigm for COVID-19 but also has potential utility in the prevention setting," Piper Sandler analyst Christopher Raymond said in a research note.
Date: Oct 02, 2021
Category: More news
Source: Google
U.S. govt stops funding for late-stage study of Inovio's COVID-19 vaccine
"With multiple authorized and robustly effective COVID vaccines available, we have long viewed INO's window of opportunity to run a trial as somewhat narrow," Piper Sandler analyst Christopher Raymond said.
Date: Apr 23, 2021
Category: More news
Source: Google
Analysts: 2 Coronavirus Stocks to Buy (And 1 to Avoid)
Piper Sandlers Christopher Raymond acknowledges that theres value in its development platform. Citing its VGX-3100 candidate, he sees proof of concept data for its use in vulvar intraepithelial neoplasia (VIN) and anal intraepithelial neoplasia (AIN) as well as top-line Phase 3 data for its use in
Date: Mar 19, 2020
Category: Health
Source: Google
Bristol-Myers bulks up cancer portfolio with $74 billion Celgene deal
This deal would seem to follow a familiar pattern of pressured large-cap biotechs finding an exit through acquisition by a larger buyer, Piper Jaffray analyst Christopher Raymond said in a research note.
Date: Jan 03, 2019
Category: Headlines
Source: Google
Speedy PD pursuit via the 'off' ramp: Acorda phase III with inhaled levodopa's got wheels
Raymond James analyst Christopher Raymond called the outcome "about what you would expect" and noted a "placebo response [that] appeared more robust" in the phase III experiment than in earlier research. Acorda plans to submit an NDA in the second quarter of this year, and included will be data from
fringement suits and if the issue is decided in court, launch may be delayed to 2018-2022. Raymond James analyst Christopher Raymond said it seems unlikely for ABP 501 to be launched by September, adding we continue to prefer the sidelines as the competitive landscape becomes increasingly complex.
The drugs new cost is about four times its cost at launch in the 1990s, said Raymond James analyst Christopher Raymond. The price hikes for Enbrel and other drugs seem to have increased in magnitude and frequency, he said.
Date: Jan 10, 2016
Category: Business
Source: Google
No downpour, but steady drizzle of FDA criticism rains on Kyndrisa parade
most took a cautionary tone similar to Leerink's Schwartz. Raymond James analyst Christopher Raymond observed that the FDA came out "with guns blazing," emphasizing the importance of the outcome to Biomarin, which previously stated that the path to 2017 profitability depends on Kyndrisa's approval.
Date: Nov 20, 2015
Category: Health
Source: Google
Youtube
jim croce-hey tomorrow-cover-c... raymond
cover of hey tomorrow by christopher raymond enjoy!
Category:
Music
Uploaded:
15 Aug, 2010
Duration:
2m 10s
LIFEHOUSE/ITS YOU AND ME/CHRISTOPHER RAYMOND....
lifehouse/its you and me/cover/ Christopher Raymond
Category:
Music
Uploaded:
06 Feb, 2011
Duration:
2m 42s
COVER-AINT NO SUNSHINE- Christopher Raymond
cover-aint no sunshine Dedicated to my daughters Nicole Bedner and Amy...
Category:
Music
Uploaded:
20 Aug, 2010
Duration:
2m 47s
cover - up on cripple creek-Christophe... Ra...
cover of -up on cripple creek- by Christopher Raymond
Category:
Music
Uploaded:
25 Sep, 2010
Duration:
4m
Qik - Mobile video by Christopher Raymond
Streamed by Christopher Raymond in Silver Spring, MD. More at qik.com ...